Chemoradiotherapy Enhances Long-Term Survival in High-Risk Endometrial Cancer
Highlight
– Adjuvant chemoradiotherapy improves 10-year overall survival (74.4% vs 67.3%) and recurrence-free survival in high-risk endometrial cancer.
– Patients with p53 abnormal tumors derive the greatest survival benefit from chemoradiotherapy.
– No significant survival advantage was observed for patients with POLE-mutated or mismatch repair-deficient tumors with added chemotherapy.
– Molecular classification is critical in treatment tailoring due to differential chemotherapy benefit and toxicity considerations.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.